NON-ALCOHOLIC STEATOHEPATITIS

This study tested a new drug, ARO-HSD, in 50 healthy people and patients with NASH, a serious fatty liver disease. The main goal was to see if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and dosing, not on curing the disea…

This study tested a new drug called J2H-1702 in 87 adults with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. The goal was to see if the drug is safe and if it can reduce liver fat and stiffness after 12 weeks of treatment compared to a placebo. Participants…

This study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also measuring if the drug could improve fibrosis. Results help guide future resea…

This study tested a daily pill called MGL-3196 in 125 adults with NASH, a serious liver condition caused by fat buildup. The main goal was to see if the drug could reduce liver fat after 12 weeks compared to a placebo. Researchers also tracked side effects to check safety.

This study tested whether combining a new liver medicine (NNC0194-0499) with semaglutide (a diabetes and weight-loss drug) can reduce liver scarring in people with non-alcoholic steatohepatitis (NASH). About 700 adults took weekly injections of either the combo, another weight-lo…

This early-stage trial tested the safety and tolerability of a new drug called J2H-1702 in 100 healthy men. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers gave single and multiple doses to see how the body processes th…

This study tested a new ultrasound feature that measures liver fat and compared it to the standard MRI method. 60 adults with or at risk for fatty liver disease had both scans. The goal was to see if the ultrasound could give similar results to the MRI, which could make liver fat…

This study checked if a special MRI scan called LiverMultiScan gives the same results when a person is scanned twice on the same machine or on different machines. 61 adults with various liver diseases took part. The goal was to see if the scan reliably measures liver fat, iron, a…

This study looked at how the body processes efinopegdutide, a potential drug for fatty liver disease, in people with moderate to severe liver damage compared to healthy people. A total of 22 adults received a single dose, and researchers measured drug levels and safety. The goal …

This study examined 263 patients with NASH (a type of fatty liver disease) to see how factors like age, other health problems, and medications relate to the severity of liver scarring. Researchers reviewed medical records from 2013 to 2020. The goal was to better understand which…

This early-phase study tested a single dose of the experimental drug J2H-1702 in 16 healthy women aged 19 to 45. The main goal was to check safety and how the body processes the drug. This is a first step toward possibly treating non-alcoholic steatohepatitis (NASH), a serious fa…

This early-stage study tested the safety and how the body processes a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored for side effects and drug levels in the blood. The goal was not to treat any di…

This study tested a new ultrasound feature that measures liver fat in children and teens (ages 5-21) with or at risk for non-alcoholic fatty liver disease. Researchers compared the ultrasound results to standard MRI scans to see if the simpler, cheaper method works well. The goal…